First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis.

ABSTRACT: BACKGROUND:It remains unknown which is the optimal first-line treatment regimen for patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). We performed a network meta-analysis to address this important issue. METHODS:PubMed, Embase, Cochrane Library, Web of Science and major international scientific meetings were searched for relevant randomized controlled trials (RCTs). Progression-free survival (PFS) data was the primary outcome of interest, and overall survival (OS) and serious adverse events (SAEs) were the secondary outcomes of interests, reported as hazard ratio (HR) or odds ratio (OR) and 95% confidence intervals (CIs). RESULTS:25 RCTs with a total of 5005 patients randomized to receive seven treatments were included in the meta-an

SUBMITTER: Zhang H 

PROVIDER: S-EPMC6776360 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature